ES2124247T3 - Conjugado de calcitonina y de polietilenglicol. - Google Patents

Conjugado de calcitonina y de polietilenglicol.

Info

Publication number
ES2124247T3
ES2124247T3 ES92401164T ES92401164T ES2124247T3 ES 2124247 T3 ES2124247 T3 ES 2124247T3 ES 92401164 T ES92401164 T ES 92401164T ES 92401164 T ES92401164 T ES 92401164T ES 2124247 T3 ES2124247 T3 ES 2124247T3
Authority
ES
Spain
Prior art keywords
calcitonin
conjugate
polyethylene glycol
compound
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92401164T
Other languages
English (en)
Inventor
Henri Wantier
Fabienne Mathieu
Marc Baudrihaye
Clercq Pierre De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Application granted granted Critical
Publication of ES2124247T3 publication Critical patent/ES2124247T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN CONJUGADO DE CALCITONITA O UN POLIPEPTIDO ANALOGO QUE POSEE SUSTANCIALMENTE LA MISMA SECUENCIA DE AMINOACIDOS QUE UNA CALCITONINA NATURAL Y UNA ACTIVIDAD BIOLOGICA DE IGUAL NATURALEZA, CON UNO O VARIOS COMPUESTO(S), COMPRENDIENDO CADA UNO O VARIOS POLIMERO(S) DE POLIETILENO GLICOL POR ENLACE COVALENTE DE DICHO O DICHOS COMPUESTO(S) CON RESPECTIVAMENTE UNO O AL MENOS UN GRUPO CARBOXILO LIBRE DE LA CALCITONINA O SU ANALOGO.
ES92401164T 1991-04-23 1992-04-23 Conjugado de calcitonina y de polietilenglicol. Expired - Lifetime ES2124247T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR919104990A FR2675807B1 (fr) 1991-04-23 1991-04-23 Conjugue de calcitonine et de polyethylene glycol.

Publications (1)

Publication Number Publication Date
ES2124247T3 true ES2124247T3 (es) 1999-02-01

Family

ID=9412158

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92401164T Expired - Lifetime ES2124247T3 (es) 1991-04-23 1992-04-23 Conjugado de calcitonina y de polietilenglicol.

Country Status (5)

Country Link
EP (1) EP0511903B1 (es)
AT (1) ATE172216T1 (es)
DE (1) DE69227276T2 (es)
ES (1) ES2124247T3 (es)
FR (1) FR2675807B1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19514087A1 (de) * 1995-04-13 1996-10-17 Deutsches Krebsforsch Konjugat aus einem Wirkstoff, einem Polyether und ggfs. einem nicht als körperfremd angesehenen, nativen Protein
KR100345214B1 (ko) * 1999-08-17 2002-07-25 이강춘 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US20030114383A1 (en) * 2001-11-01 2003-06-19 Girish Shah Calcitonin-like sequence expressed by gonadotropes of the anterior pituitary
AU2003236521A1 (en) 2002-06-13 2003-12-31 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
RU2527893C2 (ru) 2004-07-19 2014-09-10 Биокон Лимитед Инсулин-олигомерные конъюгаты, их препараты и применения
WO2008151512A1 (fr) * 2007-06-12 2008-12-18 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. Dérivés de calcitonine de saumon linéaires, pégylés, spécifiques de site
RU2453332C2 (ru) 2007-10-16 2012-06-20 Байокон Лимитид Твердая фармацевтическая композиция (варианты) и способ контроля концентрации глюкозы с ее помощью, способ получения твердой фармацевтической композиции (варианты), таблетка (варианты) и способ получения амфорных частиц
ITRM20080551A1 (it) * 2008-10-15 2010-04-16 Univ Catania Derivati anfifilici del poliossietilenglicole (peg), procedimento di preparazione e loro usi nella preparazione di sistemi farmaceutici.
CN104774327A (zh) * 2015-04-08 2015-07-15 苏州市兴邦化学建材有限公司 一种大分子量甲基丙烯酸聚乙二醇单甲醚的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
WO1985003934A1 (fr) * 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Proteine modifiee chimiquement et son procede de preparation
JP2997004B2 (ja) * 1989-05-26 2000-01-11 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
DK0400472T3 (da) * 1989-05-27 1996-05-13 Sumitomo Pharma Fremgangsmåde til fremstilling af polyethylenglycolderivater og modificeret protein

Also Published As

Publication number Publication date
ATE172216T1 (de) 1998-10-15
EP0511903B1 (fr) 1998-10-14
EP0511903A2 (fr) 1992-11-04
DE69227276D1 (de) 1998-11-19
FR2675807A1 (fr) 1992-10-30
DE69227276T2 (de) 1999-06-02
FR2675807B1 (fr) 1994-07-01
EP0511903A3 (en) 1993-08-11

Similar Documents

Publication Publication Date Title
ES2124247T3 (es) Conjugado de calcitonina y de polietilenglicol.
ATE120374T1 (de) Markierte polypeptidderivate.
MX9202030A (es) Expresion recombinante de subunidades de analogo de exotoxina de colera.
PT788509E (pt) Derivados peptidicos terapeuticos
ATE144284T1 (de) Verbesserte aktivierung von rekombinanten proteinen
DK0640622T3 (da) Polysaccharidderivat og lægemiddelbærer
CA2094027A1 (en) Osteogenic peptides
FR2669930B1 (es)
ATE125269T1 (de) Radiomarkierte peptide mit antikoagulanswirkung.
ATE223481T1 (de) Peptid der löslichen form von acetylcholinesterase mit aktivität als calciumkanalmodulator
UA32522C2 (uk) Ліофілізована протипухлинна композиція і стерильна водна композиція для ін'єкцій на її основі
ATE81345T1 (de) Synthetische atriale peptide.
DE68922438D1 (de) Härtbare Polymerzusammensetzung.
AU1431188A (en) Dihydropyridine - pyridinium salt-type redox amino acids and peptides containing them
DE68921664D1 (de) Härtbare Polymer-Zusammensetzung.
DE68914304D1 (de) Härtbare Polymerzusammensetzung.
EP0416035A4 (en) Amphiphilic peptides and use thereof
DE59208622D1 (de) Dentalwerkstoffe auf Basis von (Meth)-Acrylaten
ATE93527T1 (de) Peptide und deren benutzung.
IT8819791A0 (it) Peptidi ad attivita' farmaceutica.
EP0490383A3 (en) Peptides of the hiv-gag protein, their preparation and use
DE69534738D1 (de) Leukocyten-aktivierender Faktor
ATE175213T1 (de) Ch0ndromodulin-ii protein
DE69613086D1 (de) Antigenen Peptide mit Glycinsubstitution
DE3869939D1 (de) Biologisch wirksame peptide.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 511903

Country of ref document: ES